drugset / Trial / NCT03405142

Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer

NCT03405142

Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

This phase 2 trial studies how well panitumumab-IRDye800 works in identifying head and neck cancer that has spread to the lymph nodes in patients with head and neck cancer. Panitumumab-IRDye800 may help surgeons to identify metastatic lymph nodes during surgical removal of the primary tumor and/or lymph nodes of the neck with equal or better accuracy than the current methods.

Timeline

Start
2019-08-01
Primary completion
2019-12-04
Completion
2021-04-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Panitumumab-IRDye800 Diagnostic / imaging agent 50 mg Intravenous
Subject Technetium Tc 99m Tilmanocept Diagnostic / imaging agent 74 mbq Other